BR9509190A - Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano - Google Patents

Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano

Info

Publication number
BR9509190A
BR9509190A BR9509190A BR9509190A BR9509190A BR 9509190 A BR9509190 A BR 9509190A BR 9509190 A BR9509190 A BR 9509190A BR 9509190 A BR9509190 A BR 9509190A BR 9509190 A BR9509190 A BR 9509190A
Authority
BR
Brazil
Prior art keywords
immune response
chitosan
enhance
influenza virus
composition
Prior art date
Application number
BR9509190A
Other languages
English (en)
Inventor
Steven Neville Chatfield
Original Assignee
Medeva Holdings Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv
Publication of BR9509190A publication Critical patent/BR9509190A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9509190A 1994-10-04 1995-09-21 Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano BR9509190A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9419979A GB9419979D0 (en) 1994-10-04 1994-10-04 Vaccine compositions
PCT/GB1995/002231 WO1996010421A1 (en) 1994-10-04 1995-09-21 Vaccine compositions

Publications (1)

Publication Number Publication Date
BR9509190A true BR9509190A (pt) 1997-10-21

Family

ID=10762310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509190A BR9509190A (pt) 1994-10-04 1995-09-21 Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano

Country Status (17)

Country Link
US (1) US6048536A (pt)
EP (1) EP0784485B8 (pt)
JP (1) JP4240237B2 (pt)
KR (1) KR100373593B1 (pt)
CN (1) CN1097467C (pt)
AT (1) ATE229816T1 (pt)
AU (1) AU710930B2 (pt)
BR (1) BR9509190A (pt)
CA (1) CA2201598C (pt)
DE (1) DE69529224T2 (pt)
DK (1) DK0784485T3 (pt)
ES (1) ES2192582T3 (pt)
GB (1) GB9419979D0 (pt)
MX (1) MX9702336A (pt)
NZ (1) NZ292953A (pt)
TW (1) TW426521B (pt)
WO (1) WO1996010421A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
AU754675B2 (en) * 1995-11-01 2002-11-21 Archimedes Development Limited Influenza vaccine compositions
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
JP4484969B2 (ja) * 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US5980912A (en) * 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
AU771525B2 (en) * 1997-03-25 2004-03-25 Zonagen, Inc. Chitosan induced immunopotentiation
WO1998042374A1 (en) * 1997-03-25 1998-10-01 Zonagen, Inc. Chitosan induced immunopotentiation
KR20060111731A (ko) 1997-08-05 2006-10-27 스트레스젠 바이오테크놀러지스 코포레이션 사람 유두종 바이러스 항원과 스트레스 단백질을 포함하는융합 단백질을 포함하는 조성물에 의해 유도된 사람 유두종바이러스 항원에 대한 면역 반응
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
NZ514323A (en) * 1999-03-24 2003-03-28 Secr Defence A immunostimulant containing an acitive agent and an adjuvant which increases the effect of the active agent
CA2378097A1 (en) 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
JP2003519668A (ja) 2000-01-14 2003-06-24 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング
DK1296711T3 (da) 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
ITMI20010571A1 (it) * 2001-03-19 2002-09-19 Grisotech S A Vaccini assorbibili per via trans-mucosale
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
ATE426412T1 (de) * 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
CN1301131C (zh) * 2003-04-11 2007-02-21 上海欣安基因免疫与疫苗研究开发有限公司 一种病毒性心肌炎基因疫苗及其制备方法和应用
EP1620732A2 (en) * 2003-04-30 2006-02-01 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US20060177468A1 (en) * 2005-01-05 2006-08-10 Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine Delivery vehicles, bioactive substances and viral vaccines
CN100425288C (zh) * 2005-01-28 2008-10-15 北京金迪克生物技术研究所 鼻腔喷雾型流感病毒灭活疫苗及其制备方法
CA2552596A1 (en) * 2005-08-09 2007-02-09 Solvay Pharmaceuticals B.V. Methods and systems for determining mid-value titers
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
CN101450208B (zh) * 2008-12-31 2011-08-31 中国人民解放军军事医学科学院微生物流行病研究所 喷鼻免疫流感多价疫苗的制备及其方法
EP2308506A1 (en) * 2009-10-02 2011-04-13 Mucosis B.V. Adjuvanted intranasal vaccine formulations
WO2016199904A1 (ja) * 2015-06-10 2016-12-15 国立大学法人東京大学 ワクチン用アジュバント、ワクチン、及び免疫誘導方法
GB2596820A (en) * 2020-07-07 2022-01-12 Spicona Inc Combination vaccine
GB202412729D0 (en) * 2024-08-30 2024-10-16 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Mucosal vaccine adjuvant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
US5169840A (en) * 1991-03-27 1992-12-08 Nobipols Forskningsstiftelse Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation
JP3109886B2 (ja) * 1991-12-13 2000-11-20 デンカ生研株式会社 経鼻接種用ワクチン
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
JPH06166635A (ja) * 1992-06-18 1994-06-14 San Five Kk 免疫アジュバント
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions

Also Published As

Publication number Publication date
JP4240237B2 (ja) 2009-03-18
JPH10506405A (ja) 1998-06-23
EP0784485B1 (en) 2002-12-18
TW426521B (en) 2001-03-21
US6048536A (en) 2000-04-11
DK0784485T3 (da) 2003-04-07
CN1097467C (zh) 2003-01-01
NZ292953A (en) 2001-03-30
AU3526995A (en) 1996-04-26
KR100373593B1 (ko) 2003-05-09
MX9702336A (es) 1997-06-28
ES2192582T3 (es) 2003-10-16
DE69529224T2 (de) 2003-07-24
GB9419979D0 (en) 1994-11-16
CA2201598C (en) 2006-12-12
DE69529224D1 (de) 2003-01-30
ATE229816T1 (de) 2003-01-15
AU710930B2 (en) 1999-09-30
CN1159761A (zh) 1997-09-17
CA2201598A1 (en) 1996-04-11
EP0784485B8 (en) 2003-05-02
WO1996010421A1 (en) 1996-04-11
KR970706018A (ko) 1997-11-03
EP0784485A1 (en) 1997-07-23

Similar Documents

Publication Publication Date Title
BR9509190A (pt) Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano
BR9611218A (pt) Composição de vacina produto farmacêutico processos para imunizar um hospedeiro contra a infecção e para realçar uma resposta imunológica
McNeela et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery
McNeela et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
CA2311492A1 (en) Vaccines with an ltb adjuvant
DK1144001T3 (da) Inaktiveret influenzavirusvaccine til nasal eller oral indgivelse
US20090252762A1 (en) novel proteosome-liposaccharide vaccine adjuvant
de Haan et al. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration
TW200722101A (en) Novel composition
DK0764029T3 (da) Proteinadjuvanser
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
Glathe et al. Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle-aged and elderly people
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
Wareing et al. Route of administration is the prime determinant of IgA and IgG2a responses in the respiratory tract of mice to the cold-adapted live attenuated influenza A donor strain A/Leningrad/134/17/57
Alpar et al. Quil-A-Chitosan: A novel mucosal adjuvant
SG160386A1 (en) Novel composition

Legal Events

Date Code Title Description
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
B25A Requested transfer of rights approved

Free format text: WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTER LIMITED (GB)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ARCHIMEDES DEVELOPMENT LIMITED (GB)

Free format text: ALTERADO DE: WEST PHARMACEUTICAL SERVICES DRUG DELIVERY AND CLINICAL RESEARCH CENTRE LIMITED

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/09/2015